Chapter 2 - Commentary by Anagnostou V and Luke JJ 285 A 1. Hummelink, K. et al. PD-1T TILs as a predictive biomarker for clinical benefit to PD-1 blockade in patients with advanced NSCLC. Clin Cancer Res 2022;28:4893–906. 2. Thommen, D.S. et al. A transcriptionally and functionally distinct PD-1(+) CD8(+) T cell pool with predictive potential in non- small cell lung cancer treated with PD-1 blockade. Nat Med 2018;24:994–1004. 3. Anagnostou, V. et al. Immuno-oncology trial endpoints: capturing clinically meaningful activity. Clin Cancer Res 2017;23:4959–69. 4. Fridman, W.H., Meylan, M., Petitprez, F., Sun, C.M., Italiano, A., Sautes-Fridman, C. B cells and tertiary lymphoid structures as determinants of tumor immune contexture and clinical outcome. Nat Rev Clin Oncol 2022;19:441–57. 5. Cercek, A. et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med 2022;386:2363–76. 6. Doroshow, D.B. et al. PD-L1 as a biomarker of response to immune checkpoint inhibitors. Nat Rev Clin Oncol 2021;18:345–62. 7. Brahmer, J. et al. Nivolumab versus docetaxel in advanced squamous cell non-small cell lung cancer. N Engl J Med 2015;373:123–35. 8. Rittmeyer, A. et al. Atezolizumab versus docetaxel in patients with previously treated nonsmall cell lung cancer (OAK): a phase III, open-label, multicenter, randomized controlled trial. Lancet 2017;389:255–65. 9. Litchfield, K. et al. Meta-analysis of tumor- and T-cell–intrinsic mechanisms of sensitization to checkpoint inhibition. Cell 2021;184:596–614. 10. McGrail, D.J. et al. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann Oncol 2021;32:661–72. 11. Anagnostou, V., Bardelli, A., Chan, T.A., Turajlic, S. The status of tumor mutational burden and immunotherapy. Nature cancer 2022;3:652–6. 12. Tumeh, P.C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014;515:568–71. 13. Berry, S. et al. Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade. Science 2021;372. 14. Carstens, J.L. et al. Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer. Nat Commun 2017;8:15095. 15. Giraldo, N.A. et al. Spatial UMAP and image cytometry for topographic immuno-oncology biomarker discovery. Cancer Immunol Res 2021;9:1262–9. 16. Lopez de Rodas, M. et al. Role of tumor- infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-- small cell lung cancer. J Immunother Cancer 2022;10. 17. Gavrielatou, N. et al. Association of PD-1/PD-L1 co-location with immunotherapy outcomes in non-- small cell lung cancer. Clin Cancer Res 2022;28:360–7. 18. Lu, S. et al. Comparison of biomarker modalities for predicting response to PD-1/PD-L1 checkpoint blockade: a systematic review and meta-analysis. JAMA Oncol 2019;5:1195–204. 19. Schurch, C.M. et al. Coordinated cellular neighborhoods orchestrate antitumoral immunity at the colorectal cancer invasive front. Cell 2020;183:838. 20. Caushi, J.X. et al. Transcriptional programs of neoantigen-specific TIL in anti–PD-1— treated lung cancers. Nature 2021;596:126–32.
RkJQdWJsaXNoZXIy MTk4NDMw